BioCentury | Oct 3, 2016
Finance

Dressed in black

Every single market cap band finished in the black in 3Q16, a feat not accomplished since the first quarter of 2014. M&A and a string of positive clinical and regulatory news fueled the 3Q16 rally...
BC Week In Review | Aug 15, 2016
Company News

Pernix Therapeutics neurology news

In July, Pernix restructured its sales organization and reduced overall headcount by 60 (about 23%). The cuts include 54 sales positions, primarily from the neurology sales team, and 6 administrative positions. Pernix prioritized and reorganized...
BioCentury | Nov 18, 2013
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 11/15 cls Cellular Dynamics International Inc. (NASDAQ:ICEL) Leerink Dan Leonard Downgrade Market perform (from outperform) -5% $14.79 Leonard downgraded but maintained his $15 target...
BioCentury | Jun 3, 2013
Regulation

Suvorexant safety

An FDA advisory committee vote may help senior officials in the Division of Neurology Products resolve a disagreement among review staff about the approvability of insomnia candidate suvorexant from Merck & Co. Inc. The reviewers...
BC Week In Review | May 13, 2013
Company News

Paladin, Pernix Therapeutics sales and marketing update

Paladin launched Silenor doxepin in Canada for the treatment and symptomatic relief of insomnia characterized by frequent nocturnal awakening and/or early morning awakenings. Health Canada approved the low-dose tricyclic doxepin in late last year. In...
BC Week In Review | Feb 18, 2013
Company News

Somaxon, Actavis neurology news

Somaxon granted Actavis non-exclusive rights to sell a generic version of insomnia drug Silenor doxepin to settle litigation between the two companies. Actavis will have rights beginning January 1, 2020, or earlier under certain circumstances...
BC Week In Review | Dec 24, 2012
Clinical News

Silenor doxepin regulatory update

Health Canada approved an NDS from Paladin Labs Inc. (TSX:PLB, Montreal, Quebec) for Silenor for the treatment and symptomatic relief of insomnia characterized by frequent nocturnal awakening and/or early morning awakenings. Paladin plans to launch...
BC Week In Review | Dec 17, 2012
Company News

Pernix Therapeutics, Somaxon deal

Specialty pharma Pernix will acquire Somaxon in stock deal that values Somaxon at $25 million. Somaxon shareholders will receive a number of Pernix shares based on the price of Pernix's shares over the 30 days...
BC Week In Review | Jul 23, 2012
Company News

Somaxon, Mylan, Zydus deal

Somaxon granted Mylan exclusive rights to sell an authorized generic version of insomnia drug Silenor doxepin in the U.S. for 180 days beginning January 2020. Under undisclosed circumstances, Mylan's right to sell the authorized generic...
BC Week In Review | Apr 30, 2012
Company News

CJ, Somaxon sales and marketing update

Somaxon granted CJ CheilJedang Corp. exclusive rights in South Korea to commercialize insomnia therapy Silenor doxepin. Somaxon will receive $600,000 up front and is eligible for sales milestones and royalties. CJ will be responsible for...
Items per page:
1 - 10 of 139